Stay updated with breaking news from Nx 5948. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BTK degrader NX-5948 has been granted Fast Track designation by the FDA to treat some adults with relapsed or refractory chronic lymphocytic leukemia or relapsed or refractory small lymphocytic lymphoma.
The FDA has granted fast track designation to the novel BTK degrader NX-5948 for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least two lines of therapy, including a BTK inhibitor and a BCL2 inhibitor.